Myeloma 2016: Panel discussion on the environment biology of myeloma
Dirk Hose et al.
Why do many MM patients relapse after being treated with targeted therapy?
Can CAR T-cells be optimised to safely treat MM patients?
The importance of anti-CD38 monoclonal antibodies for multiple myeloma
Clinical management of venetoclax in multiple myeloma